rivoceranib

Asset

Inhibits VEGFR2 signaling to suppress tumor angiogenesis.

Stage: Stage not known
Modality: Small molecule
Target: KDR; 0
Indications: 0
Trials: 1
Developer

Indications

0

In the full profile

Targets and what it contains1
Owner and partners1
Evidence for its targets1
Competitors5
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.